Double maintains 3 strategies that include CLDX - Celldex Therapeutics, Inc.
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
DNLI | 54.38% | $2.21B | -29.48% | 0.00% |
BEAM | 54.26% | $1.80B | -31.35% | 0.00% |
COGT | 51.92% | $826.59M | -19.69% | 0.00% |
RVMD | 50.08% | $7.60B | +2.00% | 0.00% |
CRNX | 49.80% | $3.03B | -32.34% | 0.00% |
CELC | 49.19% | $472.95M | -16.73% | 0.00% |
IMVT | 49.10% | $2.76B | -36.82% | 0.00% |
ATXS | 48.69% | $326.75M | -37.61% | 0.00% |
APGE | 48.06% | $2.53B | -4.22% | 0.00% |
RNA | 47.65% | $3.86B | -16.55% | 0.00% |
KRYS | 47.65% | $4.03B | -23.27% | 0.00% |
IMNM | 46.56% | $825.75M | -40.69% | 0.00% |
IDYA | 46.52% | $1.92B | -44.38% | 0.00% |
NRIX | 46.06% | $962.86M | -23.45% | 0.00% |
XNCR | 46.04% | $677.55M | -56.77% | 0.00% |
BLFS | 45.75% | $1.13B | +9.05% | 0.00% |
FENC | 45.39% | $226.47M | +19.36% | 0.00% |
ALT | 45.25% | $530.44M | +2.51% | 0.00% |
XENE | 45.21% | $2.48B | -15.90% | 0.00% |
ARWR | 44.92% | $2.31B | -35.04% | 0.00% |
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
PSQH | -0.10% | $107.02M | -32.86% | 0.00% |
SO | -0.18% | $98.42B | +14.16% | 3.23% |
DUK | -0.20% | $90.43B | +14.83% | 3.58% |
EQX | 0.23% | $3.17B | +33.65% | 0.00% |
DFDV | 0.32% | $380.05M | +2,345.35% | 0.00% |
CEF | 0.35% | - | - | 0.00% |
STNG | 0.38% | $2.10B | -48.53% | 4.80% |
UUU | -0.43% | $7.36M | +96.30% | 0.00% |
DADA | 0.45% | $513.15M | +32.00% | 0.00% |
AEM | -0.60% | $60.11B | +81.15% | 1.31% |
CIG.C | 0.64% | $2.55B | +23.82% | 0.00% |
PULM | 0.72% | $30.39M | +340.19% | 0.00% |
HUSA | -0.86% | $8.56M | -56.67% | 0.00% |
CORT | 0.89% | $7.55B | +118.26% | 0.00% |
WPM | 0.96% | $40.46B | +66.59% | 0.70% |
RLMD | 0.98% | $25.44M | -74.70% | 0.00% |
DLTR | -1.01% | $19.66B | -13.47% | 0.00% |
CL | 1.17% | $74.65B | -1.20% | 2.18% |
VSTA | -1.27% | $331.23M | +31.32% | 0.00% |
CCEC | -1.35% | $1.02B | +3.91% | 2.79% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
XBI | 64.56% | $4.89B | 0.35% |
GNOM | 58.39% | $44.34M | 0.5% |
IBB | 58.07% | $5.23B | 0.45% |
PBE | 55.21% | $229.19M | 0.58% |
ARKG | 53.17% | $980.60M | 0.75% |
IWC | 51.57% | $813.58M | 0.6% |
BBH | 51.50% | $334.99M | 0.35% |
PTH | 50.38% | $104.10M | 0.6% |
XPH | 50.14% | $153.36M | 0.35% |
FBT | 49.59% | $1.05B | 0.54% |
IWO | 48.88% | $11.46B | 0.24% |
PINK | 48.86% | $131.18M | 0.5% |
VTWO | 48.81% | $12.36B | 0.07% |
IWM | 48.80% | $62.41B | 0.19% |
KJUL | 48.53% | $119.80M | 0.79% |
KJAN | 47.16% | $288.29M | 0.79% |
IWN | 47.10% | $11.05B | 0.24% |
GSSC | 46.91% | $551.51M | 0.2% |
SCHA | 46.69% | $17.13B | 0.04% |
FYX | 46.61% | $823.34M | 0.6% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
UDN | -0.12% | $145.23M | 0.78% |
XBIL | 0.14% | $782.51M | 0.15% |
PWZ | -0.32% | $702.78M | 0.28% |
FMF | -0.32% | $157.50M | 0.95% |
IUSB | 0.34% | $32.23B | 0.06% |
GTO | -0.34% | $1.92B | 0.35% |
TAXF | -0.37% | $493.06M | 0.29% |
JCPB | -0.38% | $6.56B | 0.38% |
USDU | 0.42% | $165.88M | 0.5% |
JPLD | -0.44% | $1.20B | 0.24% |
MUNI | 0.50% | $1.98B | 0.35% |
SCHP | 0.52% | $12.68B | 0.03% |
STIP | -0.52% | $12.58B | 0.03% |
SPIP | -0.56% | $953.45M | 0.12% |
STOT | 0.57% | $235.94M | 0.45% |
FISR | -0.60% | $413.03M | 0.5% |
UCON | 0.61% | $2.97B | 0.86% |
TDTF | 0.64% | $810.82M | 0.18% |
IBMN | 0.65% | $447.67M | 0.18% |
MEAR | 0.72% | $1.08B | 0.25% |
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
CBOE | -17.23% | $23.34B | +31.58% | 1.12% |
GFI | -9.93% | $21.79B | +53.72% | 2.21% |
K | -9.88% | $28.31B | +38.89% | 2.82% |
LITB | -9.41% | $21.77M | -74.81% | 0.00% |
DRD | -8.10% | $1.21B | +68.55% | 1.94% |
FMTO | -7.87% | $5.10K | -99.92% | 0.00% |
ED | -6.76% | $36.95B | +12.52% | 3.26% |
STG | -6.38% | $32.24M | -0.16% | 0.00% |
CME | -5.76% | $97.17B | +37.77% | 3.95% |
VSA | -5.34% | $8.67M | -17.07% | 0.00% |
HMY | -5.28% | $8.93B | +71.24% | 1.16% |
DG | -5.25% | $24.53B | -10.79% | 2.13% |
AQB | -5.01% | $3.52M | -50.00% | 0.00% |
EW | -4.95% | $44.27B | -14.01% | 0.00% |
AWK | -4.92% | $27.42B | +9.74% | 2.22% |
MKTX | -4.37% | $8.44B | +11.89% | 1.32% |
AEP | -4.16% | $54.46B | +15.89% | 3.59% |
WBA | -3.46% | $9.81B | -27.03% | 4.41% |
PPC | -3.40% | $10.70B | +45.42% | 0.00% |
AU | -3.20% | $23.10B | +96.87% | 2.13% |
Current Value
$20.131 Year Return
Current Value
$20.131 Year Return
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
TAIL | -34.09% | $107.77M | 0.59% |
VIXY | -33.14% | $153.01M | 0.85% |
BTAL | -30.95% | $298.87M | 1.43% |
CLIP | -13.93% | $1.50B | 0.07% |
ULST | -12.82% | $663.99M | 0.2% |
CGSM | -12.32% | $683.80M | 0.25% |
DFNM | -11.34% | $1.56B | 0.17% |
TBLL | -11.30% | $2.26B | 0.08% |
CTA | -11.20% | $1.09B | 0.76% |
BSMW | -10.83% | $102.07M | 0.18% |
SHYM | -10.24% | $324.05M | 0.35% |
MLN | -10.19% | $523.40M | 0.24% |
AGZ | -10.05% | $607.70M | 0.2% |
IVOL | -9.90% | $358.39M | 1.02% |
GBIL | -9.84% | $6.05B | 0.12% |
MMIN | -9.65% | $479.55M | 0.3% |
SPTS | -9.31% | $5.78B | 0.03% |
GOVZ | -9.13% | $260.33M | 0.1% |
IBTM | -9.10% | $317.88M | 0.07% |
FXY | -9.02% | $857.17M | 0.4% |
Finnhub
Celldex announced new data demonstrating profound, sustained complete response and improved quality of life at 76 weeks, 7 months after the completion of dosing with barzolvolimab in chronic...
Finnhub
Presentation Operator MessageOperator Hello. Welcome to Celldex's conference call and webcast. [Operator Instructions] I would now like to turn the conference over to Sarah Cavanaugh. You may...
Yahoo
Xenon Pharmaceuticals (XENE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Yahoo
Company to host webcast on Thursday, June 12 at 6:00 pm ETHAMPTON, N.J., June 10, 2025 (GLOBE NEWSWIRE) -- Celldex (NASDAQ:CLDX) announced today that data from the Company’s Phase 2 study of barzolvolimab in chronic spontaneous urticaria will be presented at the EAACI Congress 2025 being held in Glasgow, Scotland. Abstracts will be available on the meeting website Thursday, June 12th at 6:01 pm ET/ Friday, June 13th at 12:01 am CEST. Celldex will host a webcast on Thursday, June 12th at 6:00 pm
Yahoo
HAMPTON, N.J., June 06, 2025 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced that Denice M. Torres has been elected to the company’s Board of Directors. "We are excited to welcome Denice to the Celldex Board of Directors," said Anthony Marucci, Co-founder, President and Chief Executive Officer of Celldex. "Denice’s extensive leadership experience across both the pharmaceutical and consumer healthcare sectors brings a deep operational and commercial perspective to our
Yahoo
We recently published a list of 10 Best Cancer Stocks to Invest in for Long-Term Gains. In this article, we are going to take a look at where Celldex Therapeutics, Inc. (NASDAQ:CLDX) stands against other best cancer stocks to invest in for long-term gain. Surging Cancer Cases and Costs Drive Growth in the Global Oncology […]